Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
TMaH is structurally unlike any other active CMMI model. CMS is not contracting with providers, ACOs, or health systems — it is purchasing state-level policy transformation through a cooperative agreement mechanism. The 15 selected states (Alabama, Arkansas, California, DC, Illinois, Kansas, Louisiana, Maine, Minnesota, Mississippi, New Jersey, Oklahoma, South Carolina, West Virginia, Wisconsin) each receive up to $17 million over 10 years, with the funding split roughly $8 million in the pre-implementation period (MY1–3, January 2025–December 2027) and $9 million during implementation (MY4–10, January 2028–December 2034). That is not a payment model — it is a state capacity-building grant with a VBP mandate attached.
The phased payment architecture is the most consequential design choice:
The 3-year pre-implementation runway is deliberately generous, but it is also a liability — three years of TA and infrastructure building before a single performance-contingent dollar flows to providers. States that fail to build managed care plan alignment or provider participation during MY1–3 will enter MY4 with performance measurement infrastructure but no practice transformation to show for it.
The overlap policy structure reveals an important strategic reality. TMaH can coexist with MCP and CGT without restrictions. It can coexist with IBH only if providers do not receive payments from both models simultaneously — a meaningful constraint in states where OB/GYN practices operate within behavioral health integration frameworks. The AHEAD conflict is the most restrictive: TMaH and AHEAD must operate in non-overlapping sub-state regions, and providers cannot receive both TMaH payments and AHEAD global hospital budget payments. For the five states in or adjacent to AHEAD (Massachusetts is not a TMaH state, but the principle applies wherever AHEAD operates), this creates geographic carve-out complexity that will demand explicit CMS negotiation.
For state Medicaid agencies, the core calculation is straightforward: $17 million in cooperative funding against the administrative burden of a 10-year cooperative agreement with quarterly reporting, managed care plan contracting requirements, Health Equity Plan deliverables, and a mandatory VBP transition by MY5. The marginal dollar value for large states like California or Illinois is minimal — their Medicaid maternal health spend dwarfs the award. The value proposition for those states is the TA and the federal policy cover to implement Medicaid authority changes (doula coverage, midwife fee schedule updates, 12-month postpartum coverage) they may already be pursuing.
For small or capacity-constrained states — West Virginia, Maine, Mississippi — the $17 million and the one-on-one CMS analytic support are genuinely transformative. West Virginia, with among the highest rates of substance use disorder comorbidity in maternal populations, and Mississippi, with the highest maternal mortality rate in the nation, are the states where TMaH's clinical design (SUD screening integration, hypertension home monitoring, doula coverage) most directly matches the disease burden.
For providers, the financial calculus is harder. Infrastructure payments in MY3 are not yet sized publicly — they are derived from a portion of the SMA's cooperative agreement, risk-adjusted, and subject to CMS approval. Assume a participating OB/GYN practice in a TMaH sub-state region might receive infrastructure payments in the $15,000–$50,000 range based on analogous CMMI infrastructure payment precedents. Against the cost of implementing AIM patient safety bundles, standing up a data reporting pipeline, conducting HRSN screening, and building CBO referral workflows, this is unlikely to be margin-positive in MY3. The upside-only quality incentives in MY4 are the first opportunity for net-positive returns — but providers bear all the downside of infrastructure investment for three years before that threshold is reached.
The break-even inflection point is MY4. Practices that have already invested in EHR-integrated HRSN screening, perinatal mental health protocols, and team-based care coordination (e.g., through existing PCMH, MSSP, or commercial VBC arrangements) will hit the quality benchmarks at lower marginal cost. De novo transformers will not.
Federally Qualified Health Centers (FQHCs) and Rural Health Clinics are the structurally advantaged provider types. They already carry Medicaid enrollment requirements, have existing CBO linkages, and operate in the geographic markets — rural counties, low-income urban areas — where TMaH's sub-state implementation regions will be concentrated. FQHCs that have already implemented CenteringPregnancy (group perinatal care) or have doula navigation programs are positioned to receive infrastructure payments in MY3 with minimal new investment.
Hospital systems face a more complicated picture. The "Birthing-Friendly" hospital designation is a required element — hospitals in TMaH regions that have not attained it will face pressure from their SMA partners to do so, with or without additional reimbursement. The AHEAD overlap restriction is material: any health system operating under an AHEAD global budget arrangement in a TMaH-adjacent region cannot simultaneously receive TMaH provider payments. Given that AHEAD targets high-cost, high-volume hospital markets, this restriction may functionally exclude some of the highest-acuity obstetric programs from TMaH payment participation.
Managed care organizations in TMaH states face the most complex reconfiguration. SMAs must work with MCOs to create and implement a TMaH participation plan. The MY5 VBP transition — from FFS to risk-adjusted prospective payment with quality/cost reconciliation — requires MCOs to renegotiate provider contracts, update encounter data systems, and absorb the actuarial uncertainty of a new payment methodology mid-contract cycle. MCOs that have not already built maternity-specific VBP contracting infrastructure will be at a significant operational disadvantage when the MY5 deadline arrives.
Medicare Advantage plans are not directly affected — TMaH is Medicaid/CHIP only. However, MA plans operating in TMaH states with significant dual-eligible or Medicaid managed care overlap should monitor whether TMaH's HRSN screening infrastructure and CBO referral networks become the de facto standard for maternal care navigation in those markets.
Physicians (OB-GYNs, maternal-fetal medicine specialists): The upside-only performance incentive structure in MY4 is politically safe but financially modest. The real risk for OB-GYN practices is the mandatory participation in AIM patient safety bundle implementation and "Birthing-Friendly" designation activities without guaranteed infrastructure payment sizing. Practices operating primarily in commercial or Medicare populations with Medicaid as a minority payer will have limited incentive to restructure workflows for TMaH compliance. The MFM consultation billing pathway TA (explicitly mentioned in the workforce elements) addresses a longstanding access bottleneck and could meaningfully increase revenue for specialists willing to engage.
Health systems: The 10-year model timeline is both an asset and a risk. Systems that commit to TMaH-aligned care redesign — integrating midwives and doulas into employed models, building perinatal behavioral health co-location, deploying remote monitoring for gestational hypertension — will develop durable competitive advantages in the Medicaid maternity market. Systems that treat TMaH as a compliance exercise will find themselves unable to hit MY4 quality benchmarks and locked out of the MY5 VBP upside.
Hospitals: The C-section reduction target is the sharpest financial pressure point. Low-risk cesarean delivery is explicitly named as a performance measure, weighted within the 80% quality component. At an average Medicaid payment differential of roughly $3,000–$5,000 between C-section and vaginal delivery, hospitals with high low-risk C-section rates face meaningful volume-adjusted revenue exposure if TMaH incentives successfully move practice patterns. Hospitals should model their current low-risk C-section rate against state and national benchmarks now.
Payers/MA Plans: TMaH's cooperative agreement structure does not give MCOs direct funding — they receive TA and coordinate with SMAs. MCOs that proactively build TMaH-aligned quality measure tracking (particularly depression screening and postpartum visit timeliness) into their existing HEDIS infrastructure will be positioned to demonstrate performance when MY4 incentive payments are calculated. Those that do not will find their provider networks unable to generate the claims data needed to meet cost/quality benchmarks on the timeline CMS requires.
Bottom line: TMaH is the only CMMI model explicitly targeting the Medicaid maternal health infrastructure gap, with a 10-year runway long enough to actually move population-level outcomes. The financial stakes per provider are modest in the near term. The policy stakes — mandatory VBP transition, doula coverage, HRSN screening integration, C-section rate accountability — are not. Organizations in selected states should treat MY1–3 not as a grace period but as the interval in which MY4 and MY5 competitive position is determined.